Spots Global Cancer Trial Database for Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
Official Title:
Study ID: NCT00446329
Conditions
Interventions
Study Description
Brief Summary: The 1st phase of the study will assess the acute biochemical response of PTH, calcium and phosphorus to orally administered doses of cinacalcet once (60mg) or twice (30mg x 2) per day. The 2nd phase of the study designed to evaluate the long term effects of cinacalcet on BMD (bone mineral density)and the levels of PTH, calcium, phosphorus as well as its ability to control secondary hyperparathyroidism without simultaneous administration of other vitamin D compounds.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Papageorgiou General Hospital, Thessaloniki, , Greece
Contact Details
Name: Efstathios Mitsopoulos, MD
Affiliation: Papageorgiou General Hospital, Thessaloniki, Greece
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
